Pharma-Corporate Dynamics Shape FDA's Flu Vaccine Approval Process
Original framing: “Moderna says the FDA will consider its new flu shot after resolving a public dispute - Associated Press News” — AP News (via Google News)
The dispute between Moderna and the FDA embodies a trickster dynamic: the inversion of public health as a corporate asset, where 'innovation' becomes a shield for profit while 'regulation' is framed as obstruction. This absurdity clarifies the hollow solemnity of profit-driven healthcare, exposing the paradox where safety is commodified and the public good is secondary.
The Moderna case exemplifies how corporate-pharma regulatory dynamics replicate colonial-era extractive patterns in healthcare.
Integrating traditional knowledge systems with scientific validation could create more equitable vaccine distribution frameworks while addressing historical inequities in medical research.